Wolfgang Miesbach/LinkedIn
Dec 7, 2025, 16:21
Wolfgang Miesbach: Beyond Immunosuppression – Two new ways to treat ITP
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
“Beyond Immunosuppression: Two new ways to treat ITP. David Kuter gave a great presentation at ASH 2025:
- Increase Platelet Production
The latest TPO receptor agonist, hetrombopag, now in Phase 3 trials, offers a direct pathway to boost platelet synthesis—moving away from suppression toward restoration. - Decrease Platelet Destruction
A diverse arsenal of targeted therapies can redefineour strategy:
– Anti-CD38 antibodies (daratumumab, mezagitamab)
– BAFF/BAFF-R inhibitors
– FcRn inhibitors (efgartigimod)
– BTK inhibitors (rilzabrutinib, orelabrutinib)
– Complement inhibitors + immunomodulatory approaches
– T-cell engagers and CAR-T therapies
ITP is now recognized as a disorder of both reduced production AND increased destruction—this understanding drives treatment selection toward complete remission, not just disease suppression.”
Find the full coverage of ASH25 in Hemostasis Today.
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders